Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2059 in Idiopathic Pulmonary Fibrosis
NCT07600021Phase 2Not yet recruiting
- Sponsor
- InnovStone Therapeutics
- Start
- Jun 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of SYH2059 in idiopathic pulmonary fibrosis (IPF), sponsored by InnovStone Therapeutics. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
SYH2059
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07600021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600021.